MENU
+Compare
MESO
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$17.67
Change
-$0.09 (-0.51%)
Capitalization
2.3B

MESO Mesoblast Limited Forecast, Technical & Fundamental Analysis

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions... Show more

Industry: #Biotechnology
MESO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MESO with price predictions
Jan 13, 2026

MESO in +8.83% Uptrend, rising for three consecutive days on January 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MESO advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for MESO crossed bullishly above the 50-day moving average on December 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 169 cases where MESO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MESO moved out of overbought territory on January 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where MESO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on January 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MESO as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MESO turned negative on January 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MESO broke above its upper Bollinger Band on January 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MESO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.817) is normal, around the industry mean (30.106). P/E Ratio (0.000) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (109.890) is also within normal values, averaging (322.270).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MESO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

MESO is expected to report earnings to -7 cents per share on February 26

Mesoblast Limited MESO Stock Earnings Reports
Q4'25
Est.
$-0.07
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.36
Q4'24
Beat
by $0.26
Q3'23
Missed
by $0.01
The last earnings report on November 26 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 181.02K shares outstanding, the current market capitalization sits at 2.30B.
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of biological products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Level 38, 55 Collins Street
Phone
+61 396396036
Employees
83
Web
https://www.mesoblast.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSVTX15.700.01
+0.06%
Janus Henderson Small-Mid Cap Value T
NDVRX15.910.01
+0.06%
MFS New Discovery Value R1
LMRNX34.47-0.05
-0.14%
1919 Socially Responsive Balanced I
VQNPX68.47-0.16
-0.23%
Vanguard Growth & Income Inv
LIESX21.53-0.13
-0.60%
Franklin International Equity IS

MESO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
-4.87%
QTTB - MESO
51%
Loosely correlated
-7.42%
TELO - MESO
39%
Loosely correlated
-1.48%
ALGS - MESO
34%
Loosely correlated
+6.08%
TNGX - MESO
33%
Poorly correlated
-2.06%
PYPD - MESO
32%
Poorly correlated
-5.16%
More